Epidemiology & Pathogenesis
Medullary thyroid carcinoma (MTC) accounts for 3–5% of all thyroid malignancies in the United States, with an annual incidence of ~0.5 cases per 100,000 persons. It arises from the parafollicular C cells (neural crest-derived neuroendocrine cells) responsible for calcitonin production.
MTC is broadly classified into:
- Sporadic MTC (80–85% of cases): Typically presents as a unifocal tumor in older adults (median age 50–60 years), often with local invasion at diagnosis.
- Hereditary MTC (15–20% of cases): Occurs as part of the autosomal dominant Multiple Endocrine Neoplasia type 2 (MEN2) syndromes—MEN2A (~75% of hereditary cases) and MEN2B (~5%); or as Familial MTC (FMTC), a variant of MEN2A with isolated MTC across generations. Germline RET proto-oncogene mutations are pathognomonic; >95% of hereditary cases harbor such mutations.
🔬 Key Molecular Insight: Specific codon mutations correlate strongly with disease aggressiveness and timing of prophylactic thyroidectomy (per ATA Risk Stratification). Examples:
- Highest risk (HST): Codons 883, 918 (MEN2B); M918T (~50–80% of sporadic MTCs harbor somatic M918T).
- High risk: Codons 634, 618, 620 (most common in MEN2A).
- Moderate risk: Codons 768, 790, 791, 804, 891.
Clinical Presentation: Red Flags & Nuances
While many MTCs are detected incidentally or as asymptomatic neck nodules, symptomatology often reflects local tumor burden or distant metastasis.
Common Presenting Features
| Symptom | Prevalence | Clinical Relevance |
|---|---|---|
| Palpable cervical mass | ~80–90% | Usually solitary, firm, fixed; may be associated with lymphadenopathy (ipsilateral or bilateral) |
| Persistent hoarseness | 10–20% at diagnosis (higher in advanced disease) | Indicates recurrent laryngeal nerve (RLN) invasion; warrants preoperative laryngoscopy |
| Dysphagia / Odynophagia | ~5–15% | Suggests large tumor volume or esophageal compression/invasion |
| Persistent cough / Hoarse voice >2 weeks | 5–10% | May reflect tracheal invasion or recurrent laryngeal involvement; rule out metastatic nodal disease |
| Neck pain (radiating to ear) | ~10% | Often misattributed to otalgia; should prompt evaluation for extrathyroidal extension |
| Diarrhea, flushing, or wheezing | <5% at diagnosis (higher in advanced/metastatic) | Paraneoplastic syndromes due to calcitonin, prostaglandins, or serotonin secretion |
⚠️ Red Flag: Persistent hoarseness >3–4 weeks, especially without upper respiratory infection, warrants direct laryngoscopy and thyroid evaluation.
Diagnosis & Workup: A Multimodal Algorithm
1. Initial Suspicion
- Ultrasound (US) is first-line imaging for neck masses:
- MTC US features: Hypoechoic, microcalcifications (less frequent than in papillary Ca), irregular margins, taller-than-wide shape, intranodular vascularity.
- Caveat: Calcitonin-secreting nodules may lack classic “papillary cancer” features; high suspicion required in familial settings.
2. Fine-Needle Aspiration (FNA) & Cytology
- FNA is indicated for nodules ≥1 cm with suspicious US features, or ≥1.5 cm with low-risk US.
- MTC cytology: Spindle/oval cells with granular chromatin, “amyloid material” (calcitonin-derived deposits; Alcian blue+), occasional plasmacytoid cells.
- False-negative rate ~5–10% due to heterogeneous FNA sampling.
3. Ancillary Testing on FNA Specimens
- FNA calcitonin immunocytochemistry: High sensitivity (>95%) and specificity for C-cell hyperplasia (CCH) or MTC.
- FNA washout calcitonin & CEA:
- Washout calcitonin >60 pg/mL strongly supports MTC; levels >250–500 pg/mL highly specific for malignancy.
- Washout CEA improves specificity when calcitonin is equivocal.
4. Serum Biomarkers
| Marker | Utility |
|---|---|
| Basal calcitonin | Diagnostic: Levels >100 pg/mL highly suggestive of MTC; >500 pg/mL almost diagnostic. Levels <10 pg/mL make MTC unlikely. Note: Pentagastrin-stimulated calcitonin is obsolete in most centers due to drug unavailability. |
| Stimulated calcitonin (if basal equivocal) | Use recombinant human pentagastrin (where available); otherwise, calcium stimulation test. Interpret per genotype-specific thresholds (e.g., MEN2A codon 634: cutoff ~10–20 pg/mL post-stimulation). |
| Serum CEA | Prognostic and longitudinal monitoring; doubling time <6 months predicts poor survival. |
| Chromogranin A, neuron-specific enolase (NSE) | Less specific; limited utility outside research settings. |
📌 Critical Step: All patients with confirmed or suspected MTC must undergo germline RET testing, regardless of family history. Up to 7% of apparently sporadic cases harbor germline mutations.
Staging: ATA & AJCC/UICC Systems
MTC is staged differently from differentiated thyroid cancers (DTC), and age cutoffs differ:
- AJCC/UICC 8th Edition (for MTC): No age cutoff—staging identical for all adults.
- TNM (8th ed.):
- T: Size + extrathyroidal extension (ETE)
- T1 ≤2 cm, intrathyroidal
- T2 >2–4 cm, intrathyroidal
- T3a: >4 cm, limited ETE to strap muscles
- T3b: Any size with gross ETE to sternohyoid/sternothyroid
- T4: Gross ETE to trachea, esophagus, larynx, recurrent laryngeal nerve, or continuous extension to neck soft tissues
- N: Regional node involvement (levels VI, III–V, upper mediastinal)
- M: Distant metastases (liver, lung, bone, brain)
- T: Size + extrathyroidal extension (ETE)
ATA Risk Stratification Postoperatively
Used for prognosis and surveillance planning:
| Category | Definition |
|---|---|
| Excellent Response | Undetectable calcitonin & CEA (no stimulation needed), no structural disease |
| Biochemical Incomplete Response | Elevated basal/stimulated calcitonin/CEA, but no detectable structural disease |
| Structural Incomplete Response | Detectable lesions on imaging ± elevated biomarkers |
| Indeterminate Response | Borderline/biologically discordant markers or equivocal imaging |
Hereditary Syndromes: MEN2A vs. MEN2B vs. FMTC
| Feature | MEN2A | MEN2B | FMTC |
|---|---|---|---|
| Germline RET Mutations | Codons 609, 611, 618, 620, 634 (exon 10–11); 634 most common | Codon 918 (MEN2B, ~95%); codon 883 | Codons 790, 791, 804, 904 (exon 13–15) |
| MTC Age of Onset | Childhood to adulthood (mean 20–30 y) | Very early (infancy; median 1–2 y); aggressive | Later onset (adults), slower progression |
| Pheochromocytoma | ~50% (often bilateral) | ~50% | Rare (<5%) |
| Primary Hyperparathyroidism | 20–30% (multiglandular) | Absent | Absent |
| Other Features | Cutaneous lichen amyloidosis (chronic pruritic rash, upper trunk), Hirschsprung disease | Marfanoid habitus, mucosal neuromas (lips, tongue, eyelids), intestinal ganglioneuromatosis | — |
| Prophylactic Thyroidectomy Timing (per ATA) | Codon 634: ≤5 y; codons 609/618/620: ≤1 y | ≤1 year (ideally <6 months); consider by 3–6 mo |
🧬 Testing Cascade: First-degree relatives of RET carriers require genetic counseling and testing by age 3–5 years (or at birth if mutation known in family). Negative test allows discharge from surveillance.
Management: Evidence-Based Standards
1. Primary Treatment: Surgical Resection
- Total thyroidectomy + central neck dissection (CND) is standard for all MTCs >1 cm or with suspicion of lymphatic spread.
- Prophylactic CND: Recommended in hereditary MTC when calcitonin elevated (even if nodes appear benign); optional in sporadic MTC <1 cm without US abnormalities (per 2023 ATA guidelines).
- Lateral neck dissection: Indicated for clinically or radiologically involved lateral nodes (levels II–V).
- Critical considerations:
- Intraoperative RLN monitoring strongly recommended.
- Autotransplantation of parathyroid glands to prevent hypoparathyroidism.
2. Adjuvant Therapy
| Modality | Indication | Evidence |
|---|---|---|
| External Beam Radiation (EBRT) | High-risk features: positive margins, gross ETE, extracapsular extension in nodes | Meta-analyses show improved locoregional control but no OS benefit; consider for unresectable residual disease or symptomatic nodal disease |
| (¹³¹I) MIBG | Metastatic MTC (rarely used now due to low uptake and superior alternatives) | Low response rates (<20%); largely supplanted by PRRT |
| Peptide Receptor Radionuclide Therapy (PRRT): ¹⁷⁷Lu-DOTATATE or ⁹⁰Y-DOTATOC | Somatostatin receptor–positive metastatic disease (SSTR-PET/CT+) | Phase II data show disease stabilization; not FDA-approved for MTC but used off-label. SELECT trial subanalysis supports potential role |
3. Systemic Therapy for Advanced Disease
- Tyrosine Kinase Inhibitors (TKIs):
- Vandetanib & Cabozantinib: First-line for progressive, symptomatic metastatic MTC.
- SELECT & EXIST-2 trials: Pooled ORR ~45–50%, median PFS ~30–45 months.
- Common toxicities: Diarrhea (70%), QT prolongation (vandetanib), hand-foot syndrome, hypertension.
- Pre-treatment ECG and electrolyte monitoring required.
- Vandetanib & Cabozantinib: First-line for progressive, symptomatic metastatic MTC.
- RET-Specific Inhibitors:
- Selpercatinib & Pralsetinib: Superior first-line for RET-mutant MTC (including sporadic).
- LIBRETTO-001 & RETALIATE trials: ORR ~60–70% in treatment-naïve; CNS activity.
- Better tolerability vs. multikinase inhibitors; preferred if RET mutation confirmed.
- Testing Imperative: All advanced MTCs should undergo tumor RET mutation analysis (germline + somatic) and NTRK/ALK/fusion testing.
- Selpercatinib & Pralsetinib: Superior first-line for RET-mutant MTC (including sporadic).
4. Surveillance Post-Treatment
- Biomarkers: Measure serum calcitonin & CEA every 6–12 months long-term.
- Calcitonin doubling time (DT):
- DT >20 months: Excellent prognosis
- DT 6–20 months: Intermediate risk
- DT <6 months: High mortality risk; intensify imaging (whole-body MRI, ¹⁸F-FDG PET/CT, SSTR-PET)
- Calcitonin doubling time (DT):
- Imaging:
- Baseline neck US at 6–12 mo post-op.
- CT/MRI chest/abdomen if biomarkers rise or staging was incomplete.
- Consider SSTR-PET (e.g., ⁶⁸Ga-DOTATATE) for biochemical recurrence with low-level markers.
Prognostic Factors
- Favorable: Age <55, tumor ≤2 cm, intrathyroidal, no ETE or node mets
- Poor: Age >55, large size, ETE, lymphovascular invasion, distant mets (liver/bone), DT calcitonin <6 mo
- 10-year survival:
- Stage I/II: >95%
- Stage III: ~75–85%
- Stage IV: ~20–40%
Key Takeaways for Clinicians
- MTC accounts for 3–5% of thyroid cancers but ~15% of thyroid cancer deaths.
- Suspect familial cases in all patients with MTC—RET testing is mandatory.
- Calcitonin is the most sensitive biomarker; stimulus testing (e.g., calcium/pentagastrin) rarely needed if basal calcitonin >10–20 pg/mL.
- Surgery is curative only for localized disease; multidisciplinary planning essential for advanced cases.
- Molecular profiling guides targeted therapy: RET inhibitors now first-line for advanced disease.
References (Selected)
- Wells SA Jr, et al. J Clin Endocrinol Metab. 2015;100(4):1201–1264. (ATA Guidelines)
- Robins H, et al. JAMA Oncol. 2023;9(7):e230778. (TKI outcomes update)
- Creemers MJ, et al. Eur J Endocrinol. 2021;184(2):R105–R120. (Familial MTC management)
- Elisei R, et al. Thyroid. 2023;33(1):22–34. (Biomarker dynamics & prognosis)
- Farag TS, et al. JCO Precis Oncol. 2022;6:PO.22.00117. (Real-world RET inhibitor data)
